PlumX Metrics
Embed PlumX Metrics

A Comparison of Ketamine and Midazolam as First-Line Anesthetic Infusions for Pediatric Status Epilepticus

Neurocritical Care, ISSN: 1556-0961, Vol: 40, Issue: 3, Page: 984-995
2024
  • 5
    Citations
  • 0
    Usage
  • 60
    Captures
  • 1
    Mentions
  • 9
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    5
  • Captures
    60
  • Mentions
    1
    • News Mentions
      1
      • 1
  • Social Media
    9
    • Shares, Likes & Comments
      9
      • Facebook
        9

Most Recent News

Recent Findings from Children's Hospital Philadelphia Provides New Insights into Status Epilepticus (A Comparison of Ketamine and Midazolam As First-line Anesthetic Infusions for Pediatric Status Epilepticus)

2023 NOV 09 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Daily News -- Data detailed on Epilepsy - Status Epilepticus have been

Article Description

Background: Pediatric refractory status epilepticus (RSE) often requires management with anesthetic infusions, but few data compare first-line anesthetics. This study aimed to compare the efficacy and adverse effects of midazolam and ketamine infusions as first-line anesthetics for pediatric RSE. Methods: Retrospective single-center study of consecutive study participants treated with ketamine or midazolam as the first-line anesthetic infusions for RSE at a quaternary care children’s hospital from December 1, 2017, until September 15, 2021. Results: We identified 117 study participants (28 neonates), including 79 (68%) who received midazolam and 38 (32%) who received ketamine as the first-line anesthetic infusions. Seizures terminated more often in study participants administered ketamine (61%, 23/38) than midazolam (28%, 22/79; odds ratio [OR] 3.97, 95% confidence interval [CI] 1.76–8.98; P < 0.01). Adverse effects occurred more often in study participants administered midazolam (24%, 20/79) than ketamine (3%, 1/38; OR 12.54, 95% CI 1.61–97.43; P = 0.016). Study participants administered ketamine were younger, ketamine was used more often for children with acute symptomatic seizures, and midazolam was used more often for children with epilepsy. Multivariable logistic regression of seizure termination by first-line anesthetic infusion (ketamine or midazolam) including age at SE onset, SE etiology category, and individual seizure duration at anesthetic infusion initiation indicated seizures were more likely to terminate following ketamine than midazolam (OR 4.00, 95% CI 1.69–9.49; P = 0.002) and adverse effects were more likely following midazolam than ketamine (OR 13.41, 95% CI 1.61–111.04; P = 0.016). Survival to discharge was higher among study participants who received midazolam (82%, 65/79) than ketamine (55%, 21/38; P = 0.002), although treating clinicians did not attribute any deaths to ketamine or midazolam. Conclusions: Among children and neonates with RSE, ketamine was more often followed by seizure termination and less often associated with adverse effects than midazolam when administered as the first-line anesthetic infusion. Further prospective data are needed to compare first-line anesthetics for RSE.

Bibliographic Details

Jacobwitz, Marin; Mulvihill, Caitlyn; Kaufman, Michael C; Gonzalez, Alexander K; Resendiz, Karla; Francoeur, Conall; Helbig, Ingo; Topjian, Alexis A; Abend, Nicholas S

Springer Science and Business Media LLC

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know